A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

* Participants are eligible to be included in the study only if all the following criteria apply: * Participant met all inclusion/exclusion criteria of either Protocol RLM-MD-01 (NCT03285308) or Protocol RLM-MD-02 (NCT03426345) and successfully completed the study * Able to provide written informed consent (IC) prior to any study procedures and willing and able to comply with study procedures * In the opinion of the investigator, the participant demonstrated adequate compliance with the study procedures in Study RLM-MD-01 or RLM-MD-02

* Participants are excluded from the study if any of the following criteria apply: * Participant is not willing or able to abide by the restrictions regarding concomitant medicine use * Participant is planning to receive an investigational drug (other than study treatment) or investigational device at any time during Study RLM-MD-03 * Participant has an unresolved adverse event (AE) or a clinically significant finding on physical examination, clinical laboratory test, or 12-lead electrocardiogram (ECG) that, in the investigator's opinion, would limit the participant's ability to participate in or complete the study * Any other reason that, in the investigator's opinion, would confound proper interpretation of the study or expose a participant to unacceptable risk, including renal, hepatic or cardiopulmonary disease